Cognition Therapeutics, Inc.
CGTXCognition Therapeutics, Inc. in brief
Cognition Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Purchase, New York, USA. Its market value was $70 M on 30 October 2026, which makes it the 20,053rd largest listed company in the world and the 3,705th largest in the USA on this site. It employs about 14 people and Lisa Ricciardi is its chief executive. Its shares trade under the symbol CGTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cognition Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.
Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer’s disease, or AD, and dementia with Lewy bodies, or DLB.
From the company's annual report filed with the US SEC: read the report
Cognition Therapeutics, Inc. timeline
- 2009
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed Cognition Therapeutics IncFormerly Cognition Theraputics Inc.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 October 2021; shares registered for exchange trading on 6 October 2021.
Events of Cognition Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,217 (Jan 2022) · #4,568 (Dec 2022) · #4,727 (Jul 2023) · #3,947 (Jan 2024) · #1,957 (Mar 2026) · #3,439 (Aug 2026) · #3,606 (Oct 2026) · #3,709 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 2.1×
- Free cash flow yield
- -40.5%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -68.5%
- Liabilities / assets
- 29.2%
- Profit per employee
- $-1.7 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-48M | $-23M | — |
| Dec 2024 | — | — | $-54M | $-34M | — |
| Dec 2023 | — | — | $-51M | $-26M | — |
| Dec 2022 | — | — | $-44M | $-21M | — |
| Dec 2021 | — | — | $-29M | $-12M | — |
| Dec 2020 | — | — | $-17M | $-8M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-25M | — | — | $-0.32 | — |
| Dec 2024 | $-28M | $0M | $-28M | $-0.86 | — |
| Dec 2023 | $-16M | $0M | $-16M | $-0.86 | — |
| Dec 2022 | $-19M | $0M | $-19M | $-0.91 | — |
| Dec 2021 | $-4M | $0M | $-4M | $-3.13 | — |
| Dec 2020 | $-3M | $0M | $-3M | $-23.76 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations · Listing notice
- Oct 22, 20268-KCurrent reportOther events
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 24, 20268-KCurrent reportOther events
- Jun 18, 20268-KCurrent reportShareholder vote
- Jun 4, 20268-KCurrent reportRegulation FD disclosure
- May 21, 20268-KCurrent reportOther events
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 27, 2026DEF 14AProxy statement
Official filings of Cognition Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-48 M
- Net income
- $-23 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $48 M
- Total liabilities
- $14 M
- Total equity
- $34 M
As of December-2025
Top 78 institutional investors in Cognition Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BIOS Capital Management, LP | 6,000,000 | 0 (0.00%) | 6.31% | $6 M | Nov 13, 2026 |
| 2 | DAVENPORT & Co LLC | 4,248,410 | -11,101 (-0.26%) | 4.47% | $4 M | Oct 14, 2026 |
| 3 | Vanguard Capital Management LLC | 3,438,775 | 0 (0.00%) | 3.62% | $3 M | Nov 13, 2026 |
| 4 | BlackRock, Inc. | 1,253,474 | -8,519 (-0.68%) | 1.32% | $1 M | Nov 13, 2026 |
| 5 | Chescapmanager LLC | 997,029 | 0 (0.00%) | 1.05% | $1 M | Nov 13, 2026 |
| 6 | Geode Capital Management, LLC | 911,526 | +1,520 (+0.17%) | 0.96% | $1 M | Nov 6, 2026 |
| 7 | Renaissance Technologies LLC | 587,171 | -106,117 (-15.31%) | 0.62% | $1 M | Nov 12, 2026 |
| 8 | Hilton Capital Management, LLC | 548,950 | 0 (0.00%) | 0.58% | $1 M | Nov 12, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 508,220 | 0 (0.00%) | 0.53% | $0 M | Nov 13, 2026 |
| 10 | CM Management, LLC | 425,000 | -25,000 (-5.56%) | 0.45% | $0 M | Nov 12, 2026 |
| 11 | Sigma Planning Corp | 364,765 | +2,500 (+0.69%) | 0.38% | $0 M | Oct 23, 2026 |
| 12 | State Street Corp | 348,983 | 0 (0.00%) | 0.37% | $0 M | Nov 12, 2026 |
| 13 | Tocqueville Asset Management L.P. | 230,500 | -90,000 (-28.08%) | 0.24% | $0 M | Nov 13, 2026 |
| 14 | Dauntless Investment Group, LLC | 207,714 | -163,987 (-44.12%) | 0.22% | $0 M | Nov 16, 2026 |
| 15 | American Financial Group Inc | 205,000 | 0 (0.00%) | 0.22% | $0 M | Nov 12, 2026 |
| 16 | Northern Trust Corp | 178,202 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 17 | Susquehanna International Group, LLP | 152,114 | New | 0.16% | $0 M | Nov 16, 2026 |
| 18 | Texas Capital Bank Wealth Management Services Inc | 143,296 | 0 (0.00%) | 0.15% | $0 M | Nov 9, 2026 |
| 19 | Charles Schwab Investment Management Inc | 84,940 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 20 | Corient Private Wealth LP | 81,287 | +3,061 (+3.91%) | 0.09% | $0 M | Nov 16, 2026 |
| 21 | Voss Capital, LP | 71,512 | -103,488 (-59.14%) | 0.08% | $0 M | Nov 16, 2026 |
| 22 | Marshall Wace, LLP | 71,065 | New | 0.07% | $0 M | Nov 13, 2026 |
| 23 | Morgan Stanley | 68,373 | +40,500 (+145.30%) | 0.07% | $0 M | Nov 13, 2026 |
| 24 | McAdam, LLC | 59,004 | -5,549 (-8.60%) | 0.06% | $0 M | Oct 21, 2026 |
| 25 | Fca Corp /TX | 52,536 | 0 (0.00%) | 0.06% | $0 M | Nov 12, 2026 |
Show all 78: investors 26 to 78
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jones Financial Companies Lllp | 50,661 | +10,017 (+24.65%) | 0.05% | $0 M | Nov 13, 2026 |
| 27 | BlueStem Wealth Partners, LLC | 50,000 | New | 0.05% | $0 M | Nov 13, 2026 |
| 28 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 48,000 | 0 (0.00%) | 0.05% | $0 M | Oct 27, 2026 |
| 29 | Lido Advisors, LLC | 46,149 | New | 0.05% | $0 M | Nov 4, 2026 |
| 30 | Bangor Savings Bank | 40,519 | 0 (0.00%) | 0.04% | $0 M | Oct 6, 2026 |
| 31 | Essex Financial Services, Inc. | 40,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 32 | StoneX Group Inc. | 30,945 | New | 0.03% | $0 M | Nov 3, 2026 |
| 33 | Spark Investment Management LLC | 30,200 | New | 0.03% | $0 M | Nov 13, 2026 |
| 34 | Gabelli Funds LLC | 30,000 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 35 | Bryn Mawr Trust Advisors, LLC | 29,050 | 0 (0.00%) | 0.03% | $0 M | Nov 4, 2026 |
| 36 | Citizens Financial Group Inc/ri | 27,358 | +13,679 (+100.00%) | 0.03% | $0 M | Oct 23, 2026 |
| 37 | HighTower Advisors, LLC | 26,500 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 38 | Private Management Group Inc | 24,000 | 0 (0.00%) | 0.03% | $0 M | Nov 4, 2026 |
| 39 | Vanguard Global Advisers, LLC | 23,641 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 40 | CWA Asset Management Group, LLC | 23,000 | 0 (0.00%) | 0.02% | $0 M | Oct 19, 2026 |
| 41 | Virtu Financial LLC | 22,742 | -60,692 (-72.74%) | 0.02% | $0 M | Nov 17, 2026 |
| 42 | Creative Planning | 22,200 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 43 | XTX Topco Ltd | 21,022 | -57,449 (-73.21%) | 0.02% | $0 M | Nov 16, 2026 |
| 44 | Cetera Investment Advisers | 20,830 | +980 (+4.94%) | 0.02% | $0 M | Nov 13, 2026 |
| 45 | Vestmark Advisory Solutions, Inc. | 20,080 | +10,040 (+100.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 46 | GAMCO Investors, Inc. Et Al | 20,000 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 47 | Rockefeller Capital Management L.P. | 19,231 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 48 | Northwestern Mutual Wealth Management Co | 17,467 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 49 | Focus Partners Wealth | 17,250 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 50 | Mercer Global Advisors Inc /adv | 15,951 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 51 | Bank of New York Mellon Corp | 13,462 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 52 | UBS Group AG | 13,145 | -205,391 (-93.98%) | 0.01% | $0 M | Nov 10, 2026 |
| 53 | Liberty Wealth Management LLC | 13,000 | New | 0.01% | $0 M | Nov 13, 2026 |
| 54 | Two Sigma Securities, LLC | 11,748 | New | 0.01% | $0 M | Nov 16, 2026 |
| 55 | Bradley Foster & Sargent Inc/ct | 11,722 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Vanguard Personalized Indexing Management, LLC | 11,433 | -162 (-1.40%) | 0.01% | $0 M | Nov 16, 2026 |
| 57 | Raymond James Financial Inc | 11,000 | -39,850 (-78.37%) | 0.01% | $0 M | Nov 12, 2026 |
| 58 | Chicago Partners Investment Group LLC | 10,909 | 0 (0.00%) | 0.01% | $0 M | Oct 27, 2026 |
| 59 | Captrust Financial Advisors | 10,377 | New | 0.01% | $0 M | Nov 12, 2026 |
| 60 | Elevation Point Wealth Partners, LLC | 10,040 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 61 | MML Investors Services, LLC | 10,018 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 62 | Retirement Planning Group, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 19, 2026 |
| 63 | Barry Investment Advisors, LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 14, 2026 |
| 64 | Wells Fargo & Company/mn | 6,500 | +3,500 (+116.67%) | 0.01% | $0 M | Nov 16, 2026 |
| 65 | Osaic Holdings, Inc. | 5,200 | +1,000 (+23.81%) | 0.01% | $0 M | Nov 12, 2026 |
| 66 | Fifth Third Bancorp | 5,000 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 67 | Versant Capital Management, Inc | 3,257 | 0 (0.00%) | 0.00% | $0 M | Oct 2, 2026 |
| 68 | Royal Bank Of Canada | 2,456 | New | 0.00% | $0 M | Nov 16, 2026 |
| 69 | Global Retirement Partners, LLC | 2,000 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 70 | TD Waterhouse Canada Inc. | 1,000 | New | 0.00% | $0 M | Oct 16, 2026 |
| 71 | Strategic Financial Concepts, LLC | 596 | New | 0.00% | $0 M | Nov 16, 2026 |
| 72 | JPL Wealth Management, LLC | 500 | New | 0.00% | $0 M | Nov 13, 2026 |
| 73 | Rialto Wealth Management, LLC | 490 | +31 (+6.75%) | 0.00% | $0 M | Nov 16, 2026 |
| 74 | Tower Research Capital LLC (TRC) | 100 | New | 0.00% | $0 M | Nov 16, 2026 |
| 75 | Cassaday & Co Wealth Management LLC | 100 | New | 0.00% | $0 M | Oct 27, 2026 |
| 76 | SBI Securities Co., Ltd. | 54 | +4 (+8.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 77 | FMR LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 78 | Caitong International Asset Management Co., Ltd | 1 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Cognition Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.44 M | $3 M | 2.6% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 871,598 | $1 M | 0.92% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 416,139 | $0 M | 0.44% | <0.01% | −1.2% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 275,235 | $0 M | 0.29% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 143,771 | $0 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 118,702 | $0 M | 0.12% | <0.01% | +5.6% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 84,940 | $0 M | 0.09% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 51,054 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 38,785 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 31,797 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 18,396 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cognition Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brett P. MoniaDirector | Grant or award | +25,000 | — | — | 73,500 | Form 4 |
| filed | BIOS Memory SPV I, LPDirector, 10% owner | Grant or award | +25,000 | — | — | 81,229 | Form 4 |
| filed | Peggy WallaceDirector | Grant or award | +25,000 | — | — | 111,461 | Form 4 |
| filed | Jack A. KhattarDirector | Grant or award | +25,000 | — | — | 73,500 | Form 4 |
| filed | Ellen B. RichstoneDirector | Grant or award | +25,000 | — | — | 83,500 | Form 4 |
| filed | John Brendan DoyleChief Financial Officer | Shares withheld for tax | -8,567 | $1.280 | $11 K | 618,942 | Form 4 |
| filed | Lisa RicciardiCEO & President, Director | Buy | +9,175 | $1.100 | $10 K | 1.72 M | Form 4 |
| filed | Anthony CaggianoChief Medical Officer | Buy | +10,000 | $1.110 | $11 K | 874,906 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cognition Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-3.23 reverse split
Trading halts
- 2024-12-18 14:45 UTC, code LUDP, resumed 14:50 UTC
Fails to deliver
- : 1,500 shares at $0.74
- : 4,744 shares at $0.76
- : 5,144 shares at $0.69
- : 14,638 shares at $0.73
- : 5,250 shares at $0.78
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cognition Therapeutics, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.0×Price to book 2.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-40.5%Free cash flow is -40.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.32 vs -0.86Diluted EPS -0.32 in fiscal 2025 against -0.86 the year before (report's currency).
- ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$8 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-88.6%-88.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.45 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year83.2%Diluted shares up 83.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cognition Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 37−10.8%— | 42+12.0%— | 37+22.7%— | 30+63.3%— | 19+44.1%— | 13—— | |
| General and administrative | 11−13.7%— | 12−9.2%— | 14+2.3%— | 13+31.9%— | 10+122%— | 4.5—— | |
| Operating expenses | 48−11.4%— | 54+6.4%— | 51+16.5%— | 44+52.3%— | 29+64.3%— | 17—— | |
| Operating income | −48—— | −54—— | −51—— | −44—— | −29—— | −17—— | |
| Interest expense and finance costs | — | — | — | — | 0.9−49.1%— | 1.8—— | |
| Net interest income | — | — | −0.0—— | −0.0—— | −0.9—— | −1.8—— | |
| Other non-operating income (expense) | 24+21.6%— | 20−19.8%— | 25+12.6%— | 22+31.2%— | 17+76.4%— | 9.6—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | — | |
| Net income attributable to shareholders | −23—— | −34—— | −26—— | −21—— | −12—— | −7.8—— | |
| Earnings per share, basic | -0.32—— | -0.86—— | -0.86—— | -0.91—— | -3.13—— | -23.76—— | |
| Earnings per share, diluted | -0.32—— | -0.86—— | -0.86—— | -0.91—— | -3.13—— | -23.76—— | |
| Shares, weighted average (basic) | 73+83.2%— | 40+32.3%— | 30+27.0%— | 24+355%— | 5.2+922%— | 0.5—— | |
| Shares, weighted average (diluted) | 73+83.2%— | 40+32.3%— | 30+27.0%— | 24+355%— | 5.2+922%— | 0.5—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 37+47.2%76.1% | 25−16.4%82.7% | 30−28.0%85.1% | 42−24.0%82.4% | 55+955%92.5% | 5.2—72.9% | |
| Other current assets | — | — | — | — | 0.0−52.2%0.0% | 0.0—0.3% | |
| Current assets | 48+62.4%99.2% | 30−13.6%97.8% | 34−28.2%97.3% | 48−19.2%94.5% | 59+754%99.8% | 6.9—97.0% | |
| Property, plant and equipment | 0.1−48.6%0.2% | 0.2−36.3%0.6% | 0.3+21.9%0.8% | 0.2+60.7%0.5% | 0.1−31.3%0.2% | 0.2—3.0% | |
| Right-of-use (leased) assets | 0.3−38.6%0.6% | 0.5−24.2%1.6% | 0.7−19.2%1.9% | 0.8—1.6% | — | — | |
| Total assets | 48+60.1%100% | 30−14.0%100% | 35−30.3%100% | 50−14.7%100% | 59+731%100% | 7.1—100% | |
| Accounts payable | 1.1−43.6%2.3% | 2.0−46.3%6.6% | 3.7+14.9%10.5% | 3.2−22.8%6.4% | 4.2+108%7.0% | 2.0—28.1% | |
| Current liabilities | 14+25.0%28.8% | 11+9.6%36.9% | 10+30.5%28.9% | 7.8−0.9%15.5% | 7.9+142%13.3% | 3.3—45.7% | |
| Lease liabilities (non-current) | 0.2−43.0%0.4% | 0.3−34.2%1.1% | 0.5−25.2%1.5% | 0.7—1.4% | — | — | |
| Total liabilities | 14+22.9%29.2% | 11+7.4%38.0% | 11+5.0%30.4% | 10+29.4%20.2% | 7.9−60.5%13.3% | 20—280% | |
| Retained earnings | −199—−411% | −175—−579% | −141—−402% | −115—−229% | −94—−159% | −68—−958% | |
| Shareholders' equity | 34+82.8%70.8% | 19−23.4%62.0% | 24−39.2%69.6% | 40−21.5%79.8% | 51—86.7% | −68—−958% | |
| Total liabilities and equity | 48+60.1%100% | 30−14.0%100% | 35−30.3%100% | 50−14.7%100% | 59+731%100% | 7.1—100% | |
| Shares outstanding | 89+48.5%— | 60+86.1%— | 32+10.9%— | 29+30.4%— | 22+4026%— | 0.5—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.0−66.4%— | 0.1+11.5%— | 0.1+15.7%— | 0.1−10.8%— | 0.1−5.1%— | 0.1—— | |
| Share-based compensation | 2.1−44.3%— | 3.7−13.9%— | 4.4+21.9%— | 3.6−31.1%— | 5.2+991%— | 0.5—— | |
| Cash from operating activities | −25—— | −28—— | −16—— | −19—— | −3.6—— | −3.4—— | |
| Capital expenditure | — | −0.0—— | −0.1—— | −0.2—— | −0.0—— | −0.0—— | |
| Cash from investing activities | 0.0—— | −0.0—— | −0.1—— | −0.2—— | −0.0—— | −0.0—— | |
| Debt issued | — | — | — | — | — | 0.4—— | |
| Cash from financing activities | 37+55.2%— | 24+421%— | 4.5−18.5%— | 5.5−89.6%— | 53+823%— | 5.8—— | |
| Exchange-rate effect on cash | — | — | 0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Change in cash | 12—— | −4.9—— | −12—— | −13−127%— | 50+2055%— | 2.3—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 27−19.6%— | 5.1+35.8%— | 5.1−55.6%— | 6.1−43.3%— | 11*+36.7%— | 3.8−66.9%— | 11−0.8%— | 11+2.2%— | 8.2*−29.7%— | 11—— | 12—— | 11—— | 12*—— | |
| General and administrative | 10−5.1%— | 2.3−13.4%— | 2.6+5.8%— | 2.7−9.8%— | 2.5*−1.8%— | 2.6−15.3%— | 2.5−19.5%— | 3.0−15.8%— | 2.6*−28.4%— | 3.1—— | 3.1—— | 3.5—— | 3.6*—— | |
| Operating expenses | 38−16.2%— | 7.4+15.7%— | 7.7−44.6%— | 8.8−36.0%— | 14*+27.5%— | 6.4−55.9%— | 14−4.8%— | 14−2.3%— | 11*−29.4%— | 14—— | 15—— | 14—— | 15*—— | |
| Operating income | −38—— | −7.4—— | −7.7—— | −8.8—— | −14*—— | −6.4—— | −14—— | −14—— | −11*—— | −14—— | −15—— | −14—— | −15*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | −0.0—— | −0.0*—— | |
| Other non-operating income (expense) | 22+28.2%— | 3.2+124%— | 3.8−47.5%— | 4.2−19.8%— | 10*+258%— | 1.4−68.1%— | 7.2−5.1%— | 5.3+6.9%— | 2.9*−59.1%— | 4.5—— | 7.6—— | 5.0—— | 7.0*—— | |
| Net income attributable to shareholders | −16—— | −4.1—— | −3.9—— | −4.6—— | −3.3*—— | −4.9—— | −6.7—— | −8.5—— | −7.8*—— | −9.9—— | −7.0—— | −9.2—— | −8.1*—— | |
| Earnings per share, basic | — | -0.04—— | -0.04—— | -0.05—— | — | -0.06—— | -0.11—— | -0.14—— | — | -0.25—— | -0.18—— | -0.27—— | — | |
| Earnings per share, diluted | — | -0.04—— | -0.04—— | -0.05—— | — | -0.06—— | -0.11—— | -0.14—— | — | -0.25—— | -0.18—— | -0.27—— | — | |
| Shares, weighted average (basic) | 95+22.0%— | 95+22.0%— | 91+42.3%— | 89+44.3%— | — | 78+92.9%— | 64+59.0%— | 62+83.3%— | — | 40—— | 40—— | 34—— | — | |
| Shares, weighted average (diluted) | 95+22.0%— | 95+22.0%— | 91+42.3%— | 89+44.3%— | — | 78+92.9%— | 64+59.0%— | 62+83.3%— | — | 40—— | 40—— | 34—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 31—88.4% | 31−21.8%88.4% | 34+217%87.4% | 31+89.5%86.1% | 37+47.2%76.1% | 39+78.7%90.6% | 11−62.3%54.7% | 16−52.6%69.9% | 25−16.4%82.7% | 22—79.8% | 29—83.0% | 35—89.2% | 30—85.1% | |
| Current assets | 34—98.4% | 34−20.2%98.4% | 38+101%98.5% | 36+56.6%99.1% | 48+62.4%99.2% | 43+59.8%98.8% | 19−43.2%97.1% | 23−39.8%97.3% | 30−13.6%97.8% | 27—97.3% | 34—97.6% | 38—97.7% | 34—97.3% | |
| Property, plant and equipment | 0.1—0.2% | 0.1−52.2%0.2% | 0.1−50.0%0.2% | 0.1−59.5%0.2% | 0.1−48.6%0.2% | 0.2−23.2%0.4% | 0.2−25.6%0.9% | 0.2−26.1%0.8% | 0.2−36.3%0.6% | 0.2—0.8% | 0.2—0.7% | 0.3—0.7% | 0.3—0.8% | |
| Right-of-use (leased) assets | 0.5—1.4% | 0.5+38.2%1.4% | 0.5+27.8%1.3% | 0.2−43.9%0.7% | 0.3−38.6%0.6% | 0.4−34.9%0.8% | 0.4−31.8%2.0% | 0.4−29.1%1.9% | 0.5−24.2%1.6% | 0.5—2.0% | 0.6—1.7% | 0.6—1.6% | 0.7—1.9% | |
| Total assets | 35—100% | 35−19.8%100% | 39+98.2%100% | 36+53.8%100% | 48+60.1%100% | 43+57.3%100% | 20−42.9%100% | 24−39.5%100% | 30−14.0%100% | 28—100% | 34—100% | 39—100% | 35—100% | |
| Accounts payable | 0.4—1.3% | 0.4−46.2%1.3% | 0.7−12.7%1.7% | 3.9+111%10.7% | 1.1−43.6%2.3% | 0.8−56.4%1.9% | 0.8−74.6%3.9% | 1.8−31.0%7.7% | 2.0−46.3%6.6% | 1.9—6.9% | 3.0—8.8% | 2.6—6.8% | 3.7—10.5% | |
| Current liabilities | 5.1—14.7% | 5.1−22.9%14.7% | 5.5−55.9%14.0% | 6.1−44.7%16.7% | 14+25.0%28.8% | 6.7−47.6%15.3% | 12+13.2%63.0% | 11+15.2%46.6% | 11+9.6%36.9% | 13—46.1% | 11—31.8% | 9.5—24.5% | 10—28.9% | |
| Lease liabilities (non-current) | 0.4—1.1% | 0.4+87.7%1.1% | 0.4+84.3%1.1% | 0.2−37.1%0.5% | 0.2−43.0%0.4% | 0.2−45.9%0.5% | 0.2−48.0%1.2% | 0.3−42.6%1.2% | 0.3−34.2%1.1% | 0.4—1.4% | 0.4—1.3% | 0.5—1.3% | 0.5—1.5% | |
| Total liabilities | 5.5—15.9% | 5.5−19.5%15.9% | 5.9−53.4%15.1% | 6.2−44.5%17.2% | 14+22.9%29.2% | 6.9−47.6%15.8% | 13+10.9%64.2% | 11+12.4%47.8% | 11+7.4%38.0% | 13—47.5% | 11—33.1% | 10.0—25.7% | 11—30.4% | |
| Retained earnings | −211—−607% | −211—−607% | −207—−533% | −203—−562% | −199—−411% | −195—−450% | −190—−970% | −184—−781% | −175—−579% | −167—−607% | −157—−458% | −150—−387% | −141—−402% | |
| Shareholders' equity | 29—84.1% | 29−19.9%84.1% | 33+370%84.9% | 30+144%82.8% | 34+82.8%70.8% | 37+152%84.2% | 7.0−69.5%35.8% | 12−57.5%52.2% | 19−23.4%62.0% | 14—52.5% | 23—66.9% | 29—74.3% | 24—69.6% | |
| Total liabilities and equity | 35—100% | 35−19.8%100% | 39+98.2%100% | 36+53.8%100% | 48+60.1%100% | 43+57.3%100% | 20−42.9%100% | 24−39.5%100% | 30−14.0%100% | 28—100% | 34—100% | 39—100% | 35—100% | |
| Shares outstanding | 95—— | 95+7.7%— | 95+46.3%— | 89+44.2%— | 89+48.5%— | 88+116%— | 65+62.0%— | 62+55.0%— | 60+86.1%— | 41—— | 40—— | 40—— | 32—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | 0.0*−48.1%— | 0.0*−44.4%— | — | — | 0.0*0.0%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 1.4−40.1%— | 0.3−33.3%— | 0.3−48.6%— | 0.3−43.7%— | 0.4*−33.0%— | 0.5−41.7%— | 0.6−45.9%— | 0.6−50.0%— | 0.5*−50.1%— | 0.9—— | 1.1—— | 1.2—— | 1.1*—— | |
| Cash from operating activities | −15—— | −3.3*—— | −3.1*—— | −5.5—— | −3.4*—— | −5.7*—— | −5.6*—— | −9.9—— | −8.4*—— | −6.9*—— | −6.0*—— | −7.2—— | −5.5*—— | |
| Capital expenditure | — | 0*—— | — | — | — | — | — | — | −0.0*—— | 0*—— | — | — | −0.0*—— | |
| Cash from investing activities | — | 0*—— | — | — | — | — | — | — | −0.0*—— | 0*—— | — | — | −0.0*—— | |
| Cash from financing activities | 7.0−85.3%— | −0.0*−100%— | 6.6*+779%— | −0.2−118%— | 0.6*−94.7%— | 34*+10209%— | 0.8*—— | 1.3−89.2%— | 11*+367%— | 0.3*—— | −0.1*—— | 12—— | 2.4*—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Change in cash | −8.3−147%— | −3.3*−112%— | 3.5*—— | −5.8—— | −2.8*−194%— | 28*—— | −4.9*—— | −8.6−281%— | 3.0*—— | −6.5*—— | −6.1*—— | 4.7—— | −3.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Cognition Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Material agreement 2 · Agreement ended 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Delisting noticeResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
7 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $2 M | No. 7 | Under $2 million | 28 | debt, options | SEC |
| Mar 2018 | $2 M | No. 6 | $2 to $10 million | 31 | debt, options | SEC |
| Nov 2016 | $4 M | No. 5 | $2 to $10 million | 50 | equity | SEC |
| Mar 2016 | $3 M | No. 4 | $2 to $10 million | 41 | debt, options | SEC |
| Mar 2014 | $16 M | No. 3 | $10 to $50 million | 56 | equity | SEC |
| Dec 2011 | $2 M | No. 2 | Under $2 million | 16 | equity | SEC |
| Dec 2010 | $3 M | No. 1 | $2 to $10 million | 22 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Government contracts: Cognition Therapeutics, Inc.#
No federal contracts in fiscal 2025, and $12.0 M in grants.
| Fiscal year | Contracts | Grants |
|---|---|---|
| FY2025 | $0 | $12.0 M |
| FY2024 | $0 | $13.1 M |
| FY2023 | $0 | $8.5 M |
| FY2020 | $0 | $5.8 M |
| FY2019 | $0 | $11.5 M |
| FY2018 | $0 | $8.2 M |
| FY2017 | $0 | $7.7 M |
| FY2016 | $0 | $5.5 M |
| FY2015 | $0 | $783 K |
| FY2014 | $0 | $700 K |
| FY2012 | $0 | $142 K |
| FY2010 | $0 | $198 K |
Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Cognition Therapeutics, Inc.: COGNITION THERAPEUTICS, INC. (UEI NUNHAKQ7MS86)
How Cognition Therapeutics, Inc. compares in Biotechnology
- Market cap$70 M · higher than 31% of 726
- Price / book2.0× · lower than 58% of 534
- FCF yield-40.5% · higher than 28% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cognition Therapeutics, Inc.🇺🇸 | $70 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cognition Therapeutics, Inc.? Verify and update this profile — free
Show Cognition Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.